马德里基因型评分可预测扩张型心肌病致病基因型
本研究基于西班牙1015例基因分型的扩张型心肌病或孤立性左室收缩功能不全患者,建立并外部验证(1097例)预测基因检测阳性的马德里基因型评分。评分含5项独立预测因子,预测概率从3%(无预测因子)至79%(≥4项),推导队列C统计量0.74,外部验证C统计量0.74。
要点
- 马德里基因型评分可预测扩张型心肌病/左室收缩功能不全患者基因检测阳性概率。
- 评分包含家族史、肢体导联低电压、骨骼肌病、无高血压、无左束支传导阻滞。
- 评分预测阳性概率从3%(无预测因子)至79%(≥4项预测因子)。
核心结论
- 马德里基因型评分是预测扩张型心肌病/左室收缩功能不全患者基因检测阳性结果的准确工具。
研究设计与样本
- 推导队列为西班牙1015例基因分型的扩张型心肌病/左室收缩功能不全患者,收集临床、心电图和超声心动图变量,采用多变量逻辑回归分析。
- 外部验证样本为来自马斯特里赫特和特里雅斯特注册研究的1097例基因分型患者。
主要发现
- 推导队列中377例(37%)基因检测阳性,验证队列中289例(26%)阳性。
- 推导队列中基因检测阳性的独立预测因子:扩张型心肌病家族史(OR 2.29;95%CI 1.73-3.04;P<0.001)、肢体导联低电压(OR 3.61;95%CI 2.38-5.49;P<0.001)、骨骼肌病(OR 3.42;95%CI 1.60-7.31;P=0.001)、无高血压(OR 2.28;95%CI 1.67-3.13;P<0.001)、无左束支传导阻滞(OR 3.58;95%CI 2.57-5.01;P<0.001)。
- 评分预测基因检测阳性概率从3%(所有预测因子均缺失)至79%(≥4项预测因子存在)。
- 内部验证C统计量0.74(95%CI 0.71-0.77),校准斜率0.94(95%CI 0.80-1.10);外部验证C统计量0.74(95%CI 0.71-0.78)。
临床怎么用
- 马德里基因型评分可用于扩张型心肌病/左室收缩功能不全患者,辅助判断基因检测阳性概率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although genotyping allows family screening and influences risk-stratification in patients with nonischemic dilated cardiomyopathy (DCM) or isolated left ventricular systolic dysfunction (LVSD), its result is negative in a significant number of patients, limiting its widespread adoption. OBJECTIVES: This study sought to develop and externally validate a score that predicts the probability for a positive genetic test result (G+) in DCM/LVSD. METHODS: Clinical, electrocardiogram, and echocardiographic variables were collected in 1,015 genotyped patients from Spain with DCM/LVSD. Multivariable logistic regression analysis was used to identify variables independently predicting G+, which were summed to create the Madrid Genotype Score. The external validation sample comprised 1,097 genotyped patients from the Maastricht and Trieste registries. RESULTS: A G+ result was found in 377 (37%) and 289 (26%) patients from the derivation and validation cohorts, respectively. Independent predictors of a G+ result in the derivation cohort were: family history of DCM (OR: 2.29; 95% CI: 1.73-3.04; P < 0.001), low electrocardiogram voltage in peripheral leads (OR: 3.61; 95% CI: 2.38-5.49; P < 0.001), skeletal myopathy (OR: 3.42; 95% CI: 1.60-7.31; P = 0.001), absence of hypertension (OR: 2.28; 95% CI: 1.67-3.13; P < 0.001), and absence of left bundle branch block (OR: 3.58; 95% CI: 2.57-5.01; P < 0.001). A score containing these factors predicted a G+ result, ranging from 3% when all predictors were absent to 79% when ≥4 predictors were present. Internal validation provided a C-statistic of 0.74 (95% CI: 0.71-0.77) and a calibration slope of 0.94 (95% CI: 0.80-1.10). The C-statistic in the external validation cohort was 0.74 (95% CI: 0.71-0.78). CONCLUSIONS: The Madrid Genotype Score is an accurate tool to predict a G+ result in DCM/LVSD.
引用
- Escobar-Lopez L, Ochoa JP, Royuela A, et al. Clinical Risk Score to Predict Pathogenic Genotypes in Patients With Dilated Cardiomyopathy. J Am Coll Cardiol. 2022. PMID: 36109106. doi:10.1016/j.jacc.2022.06.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。